Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

SANA
Sana Biotechnology, Inc. Common Stock
stock NASDAQ

At Close
May 14, 2025 3:59:30 PM EDT
1.78USD-1.114%(-0.02)299,129
0.00Bid   0.00Ask   0.00Spread
Pre-market
May 15, 2025 9:28:30 AM EDT
1.76USD-1.107%(-0.02)16,665
After-hours
May 14, 2025 4:46:30 PM EDT
1.77USD-0.276%(0.00)985
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 11, 2022
08:36AM EST  The Daily Biotech Pulse: Illumina Announces Multiple Partnerships, Immunome Slides On Regulatory Setback For COVID Antibody Drug, Preannouncements Pour In   Benzinga
06:56AM EST  Sana Biotechnology Inks Two Licensing Pacts For Targets Against Hematological Malignancies   Benzinga
06:04AM EST  Sana Biotechnology Obtains Exclusive License From National Institutes Of Health For CD22 CAR Construct   Benzinga
06:00AM EST  License will enable Sanas in vivo and ex vivo engineered T cell programs for B cell malignancies   GlobeNewswire Inc
Jan 10, 2022
04:33PM EST  Sana Biotech Reports Non-Exclusive License Deal With IASO Biotherapeutics, Innovent Biologics For Clinically Validated B Cell Maturation Antigen Construct; IASO Bio, Innovent To Receive Upfront Payments, Entitled For Up To $204M In Milestones   Benzinga
04:30PM EST  Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics   GlobeNewswire Inc
Jan 4, 2022
04:05PM EST  Sana Biotechnology to Present at the 40th Annual J.P. Morgan   GlobeNewswire Inc
Dec 17, 2021
08:00AM EST  Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in   PR Newswire
Dec 12, 2021
09:05AM EST  Hypoimmune CAR T cells evade both innate and adaptive immune systems in murine models, even in animals with pre-existing immunity to CAR T cells   GlobeNewswire Inc
Nov 9, 2021
11:11AM EST  Sana Biotechnology Q3 EPS $(0.46) Up From $(3.76) YoY   Benzinga
Nov 8, 2021
04:05PM EST  Announced license agreement for Beams CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs   GlobeNewswire Inc
Oct 19, 2021
09:07AM EDT  Sana Biotechnology Says Obtains Non-Exclusive License To CRISPR Cas12b Gene Editing Technology From Beam Therapeutics To Enable Engineered Cell Programs   Benzinga
09:00AM EDT  Agreement combines Beams gene editing technology with Sanas ex vivo platform   GlobeNewswire Inc
Oct 13, 2021
10:12AM EDT  Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize   PR Newswire
Sep 7, 2021
04:05PM EDT  Sana Biotechnology to Present at the Morgan Stanley 19th Annual   GlobeNewswire Inc
Aug 9, 2021
02:22AM EDT  MaxCyte Signs Clinical And Commercial License With Sana Biotechnology   RTTNews
Aug 6, 2021
08:53AM EDT  Goldman Sachs Maintains Neutral on Sana Biotechnology, Lowers Price Target to $34   Benzinga
Aug 4, 2021
04:47PM EDT  Sana Biotechnology Q2 EPS $0.32; Cash Position Of $930.8M   Benzinga
04:32PM EDT  Sana Biotechnology Q2 EPS $0.32   Benzinga
04:05PM EDT  Presented data showing immune evasion and survival after transplantation of allogeneic cells into primates without immune suppression at ISSCR 2021   GlobeNewswire Inc
Jul 15, 2021
07:29AM EDT  Sana Biotech To Establish Manufacturing Facility For Gene, Cell Therapy Candidates   Benzinga
Jul 14, 2021
04:13PM EDT  Facility to Support Allogeneic CAR T, Gene Therapy, and Stem Cell-Derived Therapies   GlobeNewswire Inc
04:10PM EDT  Sana Biotechnology Enters Long-Term Lease to Establish Manufacturing Facility to Enable Its Gene and Cell Therapy Product Candidates   Benzinga
Jun 28, 2021
09:58AM EDT  Sana Biotech Early Saturday Highlighted Presentation Of Data Showing Survival Of Transplanted Hypoimmune Stem Cells Without Immunosuppression In Non-Human Primates   Benzinga
Jun 26, 2021
10:43AM EDT  First demonstration of the survival of allogeneic iPSCs transplanted into an immunocompetent non-human primate model without the need for immune suppression   GlobeNewswire Inc
Jun 14, 2021
07:52PM EDT  at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship's Preemptive Medicine and Health Security Initiative   PR Newswire
09:15AM EDT  Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be presented during two plenary sessions at the International Society for Stem Cell Research 2021 Virtual Annual Meeting, to be held Monday, June 21 through Saturday, June 26.   GlobeNewswire Inc
Jun 2, 2021
04:05PM EDT  Sana Biotechnology to Present at the Goldman Sachs 42nd Annual   GlobeNewswire Inc
May 25, 2021
06:01AM EDT  Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological   PR Newswire
May 19, 2021
09:46AM EDT  Invaio Sciences Announces Agreement With Fundecitrus In Brazil To Combat Against Citrus Greening   RTTNews
09:04AM EDT  Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat   PR Newswire
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 6, 2021
07:49AM EDT  The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom   Benzinga
May 5, 2021
04:05PM EDT  Presented key proof of concept data for multiple platforms at AACR 2021   GlobeNewswire Inc
07:43AM EDT  The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues   Benzinga
May 4, 2021
04:05PM EDT  Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announcedthat it will webcast its presentation at the BofA Securities 2021 Healthcare Conference at 8:00 a.m. PT on Wednesday, May 12, 2021. The presentation will feature a business overview and update by Steve Harr, Sanas President and Chief Executive Officer.   GlobeNewswire Inc
08:10AM EDT  The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data   Benzinga
Apr 27, 2021
04:59PM EDT  Sana Biotechnology to Present Pre-Clinical Data at American Society of Gene & Cell Therapy Annual Meeting 2021   Benzinga
Apr 9, 2021
09:01AM EDT  Sana Biotechnology Says Presents Preclinical Data At American Association For Cancer Research Annual Meeting 2021; Will Highlight Results In Tumor Eradication   Benzinga
09:00AM EDT  Targeted in vivo gene delivery of a CAR using a CD8-specific fusogenresults in tumor eradication Hypoimmune CAR T cells protected from innate and adaptive immune cell recognition and result in tumor eradication   GlobeNewswire Inc
Mar 30, 2021
09:30AM EDT  Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion   PR Newswire
Mar 24, 2021
04:15PM EDT  Sana Biotechnology Q4 PS $(7.40), Down From $(4.94) YoY; Year-End Cash Position $412M   Benzinga
04:10PM EDT  Sana Biotechnology Reports Fourth Quarter and 2020 Financial   GlobeNewswire Inc
Mar 17, 2021
09:14AM EDT  FUJIFILM Cellular Dynamics And Sana Biotechnology Announce License Agreement For The Development Of iPSC-Derived Cell Therapies; Financial Terms Not Disclosed   Benzinga
09:00AM EDT  FUJIFILM Cellular Dynamics and Sana Biotechnology Announce License   GlobeNewswire Inc
Mar 4, 2021
08:12AM EST  The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company   Benzinga
Mar 3, 2021
07:46AM EST  The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study   Benzinga
Mar 1, 2021
11:13AM EST  JP Morgan Initiates Coverage On Sana Biotechnology with Neutral Rating, Announces Price Target of $35   Benzinga
10:14AM EST  Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2021   Benzinga
08:25AM EST  Morgan Stanley Initiates Coverage On Sana Biotechnology with Overweight Rating, Announces Price Target of $40   Benzinga
06:11AM EST  Goldman Sachs Initiates Coverage On Sana Biotechnology with Neutral Rating, Announces Price Target of $40   Benzinga
Feb 27, 2021
09:04PM EST  The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings   Benzinga
Feb 25, 2021
07:01AM EST  Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target   PR Newswire
Feb 24, 2021
07:30AM EST  The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO   Benzinga
Feb 19, 2021
07:25AM EST  The Daily Biotech Pulse: Novavax Vaccine Supply Deal, Orphan Drug Designation For Travere, COVID-19 Boost For Quidel, Opko   Benzinga
Feb 8, 2021
05:24PM EST  Sana Announces Closing of Initial Public Offering and Full   GlobeNewswire Inc
Feb 5, 2021
07:44AM EST  The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street   Benzinga
Feb 4, 2021
12:23PM EST  Sana Biotechnology Shares Open At $35; IPO Priced At $25/Share   Benzinga
10:43AM EST  Sana Biotechnology Shares Indicating $37.50   Benzinga
Feb 3, 2021
11:46PM EST  Sana Biotechnology Announced Pricing Of Upsized IPO Of 23.5 Mln Shares At $25/Shr   RTTNews
11:22PM EST  Sana Announces Upsized Pricing of Initial Public Offering   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC